The prefrontal cortex is believed to play a major role in depression and suicidal behavior through regulation of cognition, memory, recognition of emotion, and anxiety-like states, with numerous post-mortem studies documenting a prefrontal serotonergic dysregulation considered to be characteristic of depressive psychopathology. This study was carried out to detect changes in gene expression associated with both suicide and major depression using oligonucleotide microarrays (Affymetrix HG-U133 chip set) summarizing expression patterns in primarily ventral regions of the prefrontal cortex (BA44, 45, 46 and 47). A total of 37 male subjects were included in this study, of which 24 were suicides (depressed suicides = 16, nondepressed suicides = 8) and 13 were matched controls. All subjects were clinically characterized by means of psychological autopsies using structured interviews. Unique patterns of differential expression were validated in each of the cortical regions evaluated, with group-specific changes highlighting the involvement of several key neurobiological pathways that have been implicated in both suicide and depression. An overrepresentation of factors involved in cell cycle control and cell division (BA44), transcription (BA44 and 47) and myelination (BA46) was seen in gene ontology analysis of differentially expressed genes, which also highlights changes in the expression of genes involved in ATP biosynthesis and utilization across all areas. Gene misexpression in BA46 was most pronounced between the two suicide groups, with many significant genes involved in GABAergic neurotransmission. The pronounced misexpression of genes central to GABAergic signaling and astrocyte/ oligodendrocyte function provides further support for a central glial pathology in depression and suicidal behavior.
Introduction
Major depressive disorder (MDD) is among the most common of psychiatric disorders, with a 1-year prevalence of 10-15% across the population worldwide. Among MDD individuals, a lifetime mortality of 15% due to suicide demonstrates the significant impact that this debilitating disorder may have on those affected. A strong association has been noted between suicide and psychopathology, particularly in the case of mood disorders. 1 There is also a large body of evidence suggesting that neurobiological factors increase the predisposition to suicide. 2 In spite of some overlap, this neurobiological predisposition seems to be, to a considerable extent, different from that mediating risk to major depression or other psychopathological processes commonly present in suicide completers. 3 A number of investigations have illustrated the importance of the prefrontal regions in depression and suicidal behavior. The dorsolateral prefrontal cortex (DLPFC), including Brodmann area (BA) 46, has been directly implicated in depressive behaviors 4 while adjacent regions of the inferior frontal gyrus (BA44 (Broca's) and BA45), and orbitofrontal cortex (BA47) also exhibit pathological changes associated with depression 5 and appear to be functionally specialized with roles in episodic and working memory, recognition of emotion, attentivity and anxiety. Some of the most important evidence for the involvement of these areas in suicide results from post-mortem studies showing a reduction of presynaptic serotonin transporter sites in the prefrontal cortex, including BA45 and BA47. 6 This finding is complemented by the finding of increased 5-HT 1A binding in this region, primarily in BA45 and BA46. 7 It seems evident that the serotonergic dysfunction in victims of suicide that has been observed across numerous studies may stem from a characteristic series of gene expression changes in these dorsal and ventral regions of the prefrontal cortex.
A growing number of microarray-based investigations have been carried out in recent years, however relatively few have examined complex behavioral phenotypes, especially in humans. In comparison with microarray studies of schizophrenia and bipolar disorder, only a handful of studies have been reported on gene expression changes associated with major depression and completed suicide. [8] [9] [10] There is a clear need for further investigation of the gene expression changes associated with these phenotypes to gain better insight into their possible biological mechanisms. 11 We have carried out a microarray-based investigation of these brain regions in both depressed and nondepressed suicide victims in comparison with controls, to identify novel candidate systems and biological pathways that may be involved in suicide and major depression.
Materials and methods

Subjects
Brain tissue used in this study was obtained from the Quebec Suicide Brain Bank. Subjects were FrenchCanadian in origin, considered members of a homogeneous population with a well-identified founder effect. 12 All individuals were male, and groups were matched for both age and post-mortem interval (PMI). The PMI represents the time interval between the estimated time of death (derived through external body examination by the pathologist in conjunction with details supplied by history) and the time at which the brain was frozen in liquid nitrogen. A prolonged agonal state or extended illness was not determined to be present for any of the subjects. Following meningeal removal, brain tissue was cut in 1-inch coronal sections and areas of the dorsolateral (BA46) and ventromedial (BA44, BA45 and BA47) prefrontal cortices were dissected in accordance with standard neuroanatomical definitions. 13, 14 Sections were snap frozen in liquid nitrogen after the white matter was removed at 4 1C. Study approval was given by our local IRB and informed consent was obtained from next of kin. Only gray matter from the left hemisphere was used for both microarray analysis and RT validation.
Psychiatric diagnoses were obtained for subjects through the use of psychological autopsies, as described elsewhere. 15 Diagnoses were made using the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) Axis I disorders. The study sample consisted of suicides with major depression (SMD; n = 16), all of whom died during an episode of major depression; suicide victims (S; n = 8) with no lifetime history of major depression; and age-matched controls (C; n = 13) who had no history of suicidal behavior or major psychiatric diagnosis. Many of the subjects in the depressed suicide group had not been previously diagnosed at the time of death and only one subject in this group was known to have taken antidepressant medication.
Microarray analysis
Inclusion criteria for RNA samples used in analysis of gene expression combined measurement of A260/ A280 ratios ( > 1.9) and 28S/18S rRNA peak height ratios ( > 1.6) using a high-resolution electrophoresis system (Agilent 2100 Bioanalyzer, Agilent Technologies, Palo Alto, CA, USA). The Human Genome U133 Set (HG-U133 A and B) was employed in microarray analysis, consisting of B45 000 probe sets targeting over 39 000 human genome transcripts (http:// www.affymetrix.com). Normalization of GeneChip data used MAS 5.0 algorithms, with global normalization and scaling to a signal intensity of 100. Total RNA isolation, cRNA synthesis, microarray processing and data normalization was carried out following Affymetrix (Santa Clara, CA, USA) protocols.
A number of RNA and microarray quality control parameters were used in the filtering of arrays used in final analysis, including the raw noise score (RawQ), number of 'present' calls on arrays, scaling factors on arrays and 5 0 /3 0 signal ratios for both b-actin and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Outlier arrays for these quality measures could frequently be identified through use of principal component analysis (PCA). The final numbers of subjects included in data analysis were comparable between these four brain regions (BA44: C = 12, S = 6, SMD = 13; BA45: C = 11, S = 6, SMD = 12; BA46: C = 7, S = 7, SMD = 12 and BA47: C = 9, S = 7, SMD = 12).
Data analysis
Analyses of gene expression data were carried out using Genesis (GeneLogic Inc., Gaithersburg, MD, USA) and AVADIS software (Strand Genomics). Probe sets included in the data analysis were identified as 'present' (MAS 5.0 detection, P-valuesp0.04) for a minimum of 75% of the subjects in at least one of the three experimental groups to avoid misrepresentation of the sample and exclude nonspecific probe sets. All gene expression values were floored to 1 and then log 2 -transformed prior to statistical analysis. Statistically significant differences in gene expression between the three classes were determined using analysis of variance (ANOVA), while specific differences between controls (C), suicides (S) and SMD were assessed post hoc using the t-statistic for the three contrasts. Genes considered to be significantly differentially expressed were identified through an ANOVA (Pp0.01), a t-test (Pp0.01) for a particular comparison and a minimum 1.3-fold change in either direction. Average linkage hierarchical cluster analysis with a correlation distance metric was employed on significant genes to visualize gene expression changes between individuals and groups. Both the initial 'present' gene sets and those considered significant in data analysis were subjected to PCA. Analysis of gene ontology (GO) was carried out for differentially expressed genes using the gene score resampling (GSR) method in ErmineJ (v2.1.7), 10 with full resampling of ANOVA P-values and 200 000 iterations in P-value estimation for false discovery rate correction.
Real-time PCR
Total RNA from cortical areas was extracted from 10-20 mg of frozen tissue using an RNeasy Lipid Tissue Mini Kit (Qiagen Inc., Mississauga, Canada). These tissue samples were independent from those used for the microarray analysis, and were taken from adjacent tissue dissections. RNA quality was determined using an Agilent 2100 Bioanalyzer (Agilent Technologies), with low RNA integrity number (RIN) samples (RIN < 6) excluded from further analysis. Synthesis of cDNA from 400 ng of total RNA was carried out with oligo(dT)-priming using SuperScript II reverse transcriptase (Invitrogen, Groningen, The Netherlands). TaqMan gene expression assays (Applied Biosystems, Foster City, CA, USA) were used to validate microarray findings for genes of interest. The PCR reactions used 5 ng of cDNA template in a 12 ml reaction volume, and were run on an ABI 7900HT Real-Time PCR system (Applied Biosystems) according to manufacturer-specified conditions (ABI TaqMan Gene Expression Assays Protocol, Rev E). Fold changes between groups were evaluated using relative quantitation with b-actin as an endogenous control (demonstrating low variation from microarray analysis). All real-time reactions were carried out in triplicate. Real-time results were analyzed with SDS (ABI, v.2.2.1), with automatic computation of baseline and threshold fluorescence levels. Gene expression cycle threshold (C t ) values were included in analyses when values were at least 1 cycle above that of the endogenous control, and samples with high C t value standard deviations (0.3 cycles and above) were discarded from further study. Student's t-tests and Pearson's correlations (between microarray and realtime relative fold changes) were employed in statistical analysis (SPSS, v.12.0). The selection of genes for validation was carried out on the basis of their involvement in stress response, neurodevelopment, connection to neurotransmitter pathways implicated in major depression and on the significance of findings from microarray analysis. 24 .676.7 (SMD), F = 1.060, P = 0.357). There was no correlation between PMI and tissue pH within the PMI range of microarray study samples. The effect of age and PMI on quality control parameters like b-actin and GAPDH 5 0 /3 0 ratios and the number of present calls was evaluated. No significant correlation was observed between PMI and any of the quality control variables in our sample in all the regions studied. In addition, final groups were checked using ANOVA for variation in PMI, age, 3 0 /5 0 ratios for b-actin and GAPDH, and RIN in the RT sample, with no significant differences seen between groups.
Results
No
The filtering of genes considered 'present' (specified using MAS 5.0) in BA44 produced 15 788 genes, from which 140 were differentially expressed according to ANOVA and post hoc analysis. Among these, 88 genes were significant for the SMD-C comparison, 24 for the S-C comparison and 48 for the comparison between the S and SMD suicide subgroups. Calculation of overrepresentation of genes included within particular GO classes using GSR indicates an excess of factors involved in transcriptional activation, ion transporter activity, and cell cycle control and division (Table 1) . In addition, a number of genes involved in GABAergic and glutamatergic neurotransmission were identified, including subunits of the g-aminobutyric acid (GABA)-A receptor (GABRD), GABA-B receptor (GABBR2) and GABA-C receptor (GABRR1), an ionotropic glutamate receptor similar to GRIN1A (GRINL1A), and glutamate-ammonia ligase/glutamine synthetase (GLUL), an enzyme responsible for the clearance of synaptic glutamate ( Table 2 ). Second messenger systems also figured prominently among differentially expressed genes, including G-protein-coupled receptors and modulators as well as protein kinases.
For BA45, 101 genes of 15 886 present genes were deemed differentially expressed. These consisted of 60 for the SMD-C comparison, 21 for the S-C comparison and 27 for the S-SMD comparison. While factors involved in cell cycle regulation and cell maturation, as well as protein tyrosine kinases, are notably altered in expression between the three study groups in analysis of GO, by far the most significant finding for this region is an apparent dysregulation of adenosine 5 0 -triphosphate (ATP) production in the tricarboxylic acid (TCA) cycle, and associated change in expression of enzymes with ATPase activity coupled to transport of ions across the cell membrane. The a-2a adrenoreceptor (ADRA2A), a G-protein-coupled receptor that has been associated with severity of attention deficit hyperactivity disorder, 16 and protocadherin 9 (PCDH9), a calcium-dependent cell adhesion molecule, were both reduced significantly in the depressed suicides compared with controls. In contrast, synapsin II (SYN2) was seen to be elevated in depressed suicides over controls.
Analysis in BA47 was conducted on 15 303 genes after the initial filtering, showing 163 genes with significant differences in expression between the three groups. Subsequent pair-wise group analysis distinguished 102 genes as differentially expressed for the SMD-C comparison, 29 genes for the S-C comparison and 51 genes for the S-SMD comparison. The analysis of GO highlighted an overrepresentation of factors controlling cell growth and synapse formation, and is virtually identical to the adjacent BA45 in the illustration of disturbances to the mitochondrial electron transport chain and processes related to ATP biosynthesis and utilization. Among the significant genes in the region is the leptin receptor (LEPR), which was reduced in depressed suicides compared to controls along with both the S-100 calcium-binding protein, b (S100B) and catalase (CAT), central to the turnover of reactive oxygen species. A total of 15 655 genes were deemed present in the analysis for BA46, 623 of which were differentially expressed according the criteria for significance. Specifically, 140 genes were significant for the SMD-C comparison, 193 genes for the S-C comparison and 470 genes for the S-SMD comparison. The differentially expressed genes in BA46 were notably different than the other three regions in predominantly identifying factors distinguishing the suicide subgroups rather the SMD-C comparison, and in numbers significantly greater than the surrounding cortical areas. This finding is mirrored in the PCA (Figure 3b ), which separates the two suicide groups along the major (x) axis. The central theme of GO analysis focuses on myelination and nerve ensheathment by glial cells, reflected most visibly in the elevated expression of the quaking homologue gene (QKI) in nondepressed over depressed suicides. The QKI gene product is an RNA-binding protein with multiple transcripts involved in myelination, distributed in astrocytes and myelinating cells of the central nervous system (CNS). Along with the differential expression of GLUL and S100B in BA46, a large number of astrocyte-expressed sequences were observed among the set of differentially expressed genes. A number of presynaptic genes were also altered in BA46, including synaptosomal-associated protein, 25 kDa (SNAP25), synaptophysin-like protein (SYPL), synaptotagmin XIII (SYT13) and vesicleassociated membrane protein 3 (VAMP3). Concordant with wide-ranging alteration of factors associated with generalized neurotransmission were the changes in expression of receptors for both GABA and glutamate, including GABA-A receptor, a-5 (GABRA5); GABA-A receptor, b-1 (GABRB1); GABA-A receptor, d (GABRD); GABA-A receptor, g-1 and g-2 (GABRG1 and GABRG2); GABA-B receptor, 2 (GABBR2); glutamate receptor; ionotrophic; a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) 3 (GRIA3); and the glutamate receptor; ionotropic; N-methyl-Daspartate (NMDA) 2A (GRIN2A). A glial high-affinity glutamate transporter (SLC1A2) and a GABA transporter (SLC6A1) were also similarly increased in the S over SMD group (along with nearly 80% of the genes differentially expressed within this comparison). Finally, two genes involved in polyamine catabolism, spermidine/spermine N-1-acetyltransferase (SAT) and spermine oxidase (SMOX), also exhibited differential expression between the depressed and nondepressed suicide groups.
Clustering of subjects and significant genes shows general alignment with members of the same group (Figures 1a-4a) , with the exception of several depressed suicides in BA44 and the nondepressed Abbreviations: C, control; FC, fold change; S, suicide; SMD, suicide with major depression. suicide group in BA47. The separation of groups by expression levels of significant genes is evident in PCA where, apart from the unique profile in DLPFC, the most notable separation exists along the x axis between controls and depressed suicides (Figures 1b-4b) . No separation according to group is seen with the use of all present probe sets in PCA. A number of significant genes appeared to be interesting candidates based upon their biological relevance to depression and suicide and the consistency of findings across probe sets and regions (Table 2) . When focus was given to the various neurotransmitter systems, which might be anticipated to play modulatory roles in the depression phenotype, a large number of GABAergic genes were identified (particularly in BA44 and BA46). When a NetAffx query of probe sets with direct involvement in GABA signaling was examined for significance in the microarray data for these regions, 16 and 36% of GABA-related probe sets were significant at the P < 0.05 level in ANOVA for BA44 and BA46, respectively. Furthermore, 9 and 16% remained significant at the P < 0.01 level for these same regions, with seven distinct GABAergic genes identified by the probe sets in BA46. The overrepresentation of genes involved in GABA neurotransmission is exemplified by the GO analysis in BA46, where 'GABA signaling pathway' was detected as the most significant GO term associated with a particular neurotransmitter (P = 0.001, corrected P = 0.016).
While antidepressant medication was not a factor in the expression profiles for this study group, a number of individuals across the three groups had a known history of either substance dependence or abuse, suggesting the potential for a pharmacologic influence on the gene expression changes between groups. Additionally, some subjects tested positive for alcohol in toxicology exams (Table 3) . With the possibility of long-term or immediate gene expression changes induced by these psychoactive substances, separate covariates were introduced to a regression model to account for any significant effects. As listed in Table 4 , approximately 2-3% of differentially expressed genes were seen to be affected (Pp0.01) by either a history of substance dependence/abuse (16 genes) and/or toxicology for alcohol (13 genes). As only 1 of the 25 probe sets seen to be influenced by drug use did not retain significance (Pp0.01) for the effect of group in regression analysis, the influence of subject group on depression-and suicide-related expression changes is robust to any pharmacologic effects in this sample. Interestingly, the serotonin 2A receptor (HTR2A) was significantly altered in expression by both drug history and toxicology, and drug use (primarily alcohol) is common among individuals with major depression. A number of ribosomal genes and a gene known as GRB2-associated binding protein 1 were commonly identified across these brain regions (Pp0.05) along with alcohol dehydrogenase 4 (class II), p polypeptide (ADH4) in BA46, however any conclusions drawn must be limited due to the small number of individuals within groups for analyses.
Further examination of the most significant microarray findings for 10 genes of interest was carried out in independent RNA samples obtained from tissue blocks adjacent to those used in the original microarray assay. For this purpose, real-time PCR with relative quantitation of expression levels (Taqman) was employed to evaluate the reproducibility of the microarray findings. The genes selected for the validation stage were chosen on the basis of known biological activity and the significance of microarray findings. Analysis of the real-time data demonstrated similar group-level changes in expression for all selected genes: GABRG1 (BA46), GABRG2 (BA46, BA47), GLUL (BA44, BA45, BA46), PCDH9 (BA45), S100B (BA46, BA47), SAT (BA44, BA46), SLC6A1 (BA46), SMOX (BA46, BA47), QKI (BA46) and VAMP3 (BA46). The precision as measured by agreement between results of replicate real-time runs was high (mean DC t s.d. = 0.12 cycles), with 7% of samples showing a DC t s.d. in excess of 0.3 cycles. The fold changes at the validation stage ranged from 1.07-to 1.77-fold, and several of these changes exceeded those from the microarray analysis (PCDH9, S100B and SMOX). For 9 of the 16 contrasts, the most significant finding resulted from the comparison between the suicide groups with and without depression, all of these in BA46 where 75% of the significant genes were alternatively expressed between the S and SMD groups ( Table 5 ). The remainder of the validations were conducted between the depressed suicide and control groups (BA44, BA45 and BA47), which characterized the majority of significant findings in these cortical areas. While only a minority of the validation t-tests were significant, the direction of expression changes matched those of the microarray for all analyses and the correlations obtained between relative fold changes using microarray and real-time data across the 10 genes were good (mean r = 0.545, s.d. = 0.191). These correlations with the microarray data were significant (P < 0.05) for 12 of 16 gene/region evaluations, while 3 were suggestive of approach-wise correlation. In the case of VAMP3, the correlation with microarray data was relatively poor (r = 0.270, P = 0.203) despite significant t-test validation, potentially due to expression analysis of an alternative gene transcript. The variability witnessed in the agreement between the two methodological approaches is imposed by differences in cellular composition, RNA quality and the use of independent samples for confirmation of results. Brain pH did not operate as a significant covariate with group in prediction of expression level for any of the 10 genes selected for validation across these regions (Table 5) , and there was no correlation between pH and expression of b-actin, as measured through multiple probe sets, in DLPFC. Further, linear discriminant analysis in this region of expression values and pH revealed two discriminant functions, the matrix structure of which demonstrated no effect of pH for either functions (values).
Discussion
This study has detected a number of transcripts as differentially expressed (Pp0.01 for ANOVA, t-test, FCX1.3) in both dorsal and ventral regions of the prefrontal cortex. A total of 1027 transcripts, 390 for the SMD-C comparison (130 up, 260 down), 267 for the S-C comparison (184 up, 83 down) and 596 for the S-SMD comparison (449 up, 147 down), were identified among the four BAs and utilized in data visualization (clustering, PCA) and analysis of drug history/toxicology. For 10 genes of biological interest (GABRG1, GABRG2, GLUL, PCDH9, S100B, SAT, SLC6A1, SMOX, QKI and VAMP3), fold changes were consistent with microarray data across 16 gene/region combinations using quantitative real-time PCR, with the majority of these changes being significant through either correlation analysis or t-tests specific to group-wise comparisons. While real-time RT-PCR still presents formidable challenges for transcriptome analysis, 17 the general correlation between these strategies supports the biological validity of both techniques.
The S100B protein is a calcium-binding protein secreted from astrocytes that has neurotoxic effects at high concentrations. 18 The S100B protein is thought to function as a neurotrophic cytokine, conferring neuroprotective effects at lower levels of concentration. It may share function with p11 (S100A10), a molecule with a demonstrated reduction in both depressed patients and an animal model of depression which interacts with the serotonin 1B receptor. 19 The release of S100B is inversely proportional to the Abbreviations: C, control; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, fourth edition; MDD, major depressive disorder; PMI, post-mortem interval; S, suicide; SMD, suicide with major depression. uptake of glutamate, 20 suggesting that the altered expression of glutamate receptor subunits, transporters and GLUL witnessed here may be part of a larger glial deficit precipitated through multiple mechanisms. The g-1 and g-2 GABA-A receptor subunits (GABRG1 and GABRG2), GLUL and the GABA transporter (SLC6A1) are part of a larger group of genes controlling GABA synthesis, neurotransmission and turnover, many of which are misexpressed to varying degrees in these cortical areas. A recent microarray investigation 21 has documented a number of significant changes to central GABAergic and glutamatergic genes overlapping with the genes identified here. The reductions in GLUL shown for DLPFC in that study were also replicated here for three separate regions, all of which were effectively validated by qPCR analysis. Similarly, increased expression of the GABRD and GABRG2 receptor subunits was also observed, although in adjacent cortical regions (BA44 for GABRD, BA44 and BA47 for GABRG2). The expression of GABRA5, increased in the bipolar group for two brain regions, was elevated in this analysis for the depressed suicides, though only significantly in the comparison between suicide groups. Further, common GABA and glutamate-related changes in gene expression were independently identified between these studies, whose comparison is complicated by variability in significance thresholds, group-specific changes in expression levels or nonidentical direction of fold changes, however evidence points toward disruption of GABA/ glutamate signaling in the prefrontal cortex of patients with major depression. In general, a growing body of evidence supports the involvement of GABA/ glutamate in cortical regions typified by BA46 in the DLPFC. [21] [22] [23] Two genes involved in the catabolism of polyamines (SAT and SMOX), significant in several regions, suggest the possible association of suicide and depression with defects in the polyamine stress response system. Reduced expression of SAT in depressed and nondepressed suicide groups was previously shown in motor cortex, superior frontal gyrus and orbital gyrus, 9 with correspondingly reduced levels of SAT protein. A number of genes functioning in polyamine metabolism have also been implicated in schizophrenia through microarray analysis. 24 Polyamines themselves (primarily spermine but also spermidine) are known to modulate the activity of AMPA and NMDA subtype glutamate receptors. 25, 26 Putrescine can be converted to GABA through an acetylated intermediate while glutamate is capable of modification to ornithine, the precursor of putrescine. 27 Changes in levels of polyamines induced by misexpression of their biosynthetic and catabolic enzymes may therefore confer a reduced neuroprotective capacity to states of oxygen deprivation or metabolic stress in these regions.
Protocadherin 9 is a member of the cadherin superfamily of cell-cell adhesion proteins, involved in cell migration and the development of neural circuitry. 28 Cell adhesion molecules have garnered interest in research into psychiatric disorders including schizophrenia 29 and major depression 30, 31 in consideration of impaired connectivity and medication-dependent changes in gene expression for these conditions. Cellubrevin (VAMP3) is a ubiquitously expressed integral member of the SNARE complex directing general exocytosis. 32 It has been suggested that expression changes in numerous presynaptic molecules such as VAMP3 may figure centrally in schizophrenia pathogenesis. 33 The recent discovery of astrocytic vesicles containing VAMP3 that are competent in (Ca 2 þ )-directed glutamate release 34 further suggests the possible existence of astrocyte-based dysfunction in major depression. Other presynaptic genes also demonstrate altered transcriptional patterns in area 46, including SNAP-25 which can regulate GABA transport in the presence of syntaxin 1A. 35 A recent study showed both total and individual synapsins to be reduced in the hippocampus of patients with schizophrenia and bipolar disorder, as well as victims of suicide 36 while SYN2 was here observed to be elevated in depressed suicides (area 45).
Lastly, multiple probe sets for QKI identified a common pattern of downregulated expression in depressed suicides across all four brain regions studied. The QKI gene 37 is the human homologue of the mouse QKI, affected in the 'Quaking' mouse that displays severe dysmyelination of the CNS. The QKI gene product appears to function as an RNA-binding protein, interacting through KH domains with numerous transcripts controlling oligodendrocyte fate specification and myelin component metabolism. 38 Following on a recent description of genetic association at the QKI locus, 39 two studies have gone on to document significant and widespread reductions in QKI expression (both global and transcript specific) in schizophrenia patients compared with controls and in regions overlapping with those studied here (BA44 and BA46). 40, 41 This raises the intriguing possibility that a deficit in QKI common to multiple psychiatric disorders may lead to aberrant oligodendroglial development. In support of this model one microarray investigation of major depression in middle temporal gyrus (BA21) outlined reduced expression of 17 genes with roles in oligodendrocyte function. 42 A total of 16 of these genes were also significantly reduced in the DLPFC (BA46) of depressed suicides compared to controls (P < 0.05) here, with one gene (MOG) showing borderline significance (P = 0.06). Post-mortem studies of glial cell pathology in depression have reinforced this concept, although findings remain conflicted in many cases. [43] [44] [45] [46] The observation of a significant misexpression of molecules central to both GABAergic and glutamatergic neurotransmission in the cortical areas of individuals with major depression has been previously documented by several groups. 21, 23, 47 These studies follow on a body of clinical evidence showing that antidepressant medications may reduce glutamatergic activity while raising cortical GABA levels, which are seen to be reduced in major depression 48, 49 and possibly also schizophrenia. 50, 51 Since the two neurotransmitters are intimately connected by virtue of interconversion through glutamic acid decarboxylase in the synthesis of GABA from glutamate and the TCA cycle in the production of glutamate from GABA, it is difficult to disentangle the possible effects of these two molecules on the pathophysiology of depression and suicide. The most central GO-based finding for these frontal cortical areas is the misexpression of factors participating in the TCA cycle between suicide and control groups, possibly reflecting primary deficits at the level of expression of key molecules involved in both ATP production and neurotransmitter recycling, with concomitant changes in expression of particular downstream receptor subunits for these ligands. Alternatively, it is possible that a generalized reduction in glial cell number or function, as exemplified by the significantly downregulated expression of the glial-specific marker S100B in depressed suicides compared with controls across three of the four regions in this study, serves to disrupt glutamate/GABA transport, recycling and/or glutamate clearance, leading to increased cortical excitability and possible excitotoxic damage due to extracellular glutamate release.
The overall direction of gene expression changes in the ventrolateral cortical regions between these sample groups highlights notable deficits in astrocyteand oligodendrocyte-specific genes (most evident in area 46) for depressed suicides compared with controls, coinciding with altered expression of numerous GABA/glutamate receptor subunits and transporters. The significantly misexpressed genes are primarily downregulated in the depressed suicides compared to controls, while upregulated in the nondepressed suicides compared to controls. These observations are consistent with the glial transcript downregulation in depressed suicides described in GO analysis since many instances of significantly reduced expression are specific to glia-enriched gene products, while a similar relationship exists for many upregulated genes in the nondepressed suicides. It is possible that the latter group, for whom depression is considered absent or subclinical, commit suicide due to a variety of environmental stressors and/or higher levels of impulsivity which are associated with increases in genes functioning in stress response while suicide in depressed individuals is associated with a more general repression of gene expression that is also influenced by reduced levels or functioning in glia. While expression analysis was not conducted in white matter for these subjects, others have suggested approaches for the comparison of white-and gray matter-enriched transcript profiles to facilitate the discrimination between glial and neuronal changes in subsequent analyses. 52 Across the four regions, the GO terms most significantly associated with expression changes between the two suicide groups involve ATP-driven transporter activity (also central to the distinction between these groups and the control group) as well as 'synaptic vesicle transport' and 'cytokinesis'. Differences between the depressed suicides and controls figure most prominently in processes such as 'cell maturation' and 'immune cell activation' while genes altered in expression between nondepressed suicides and controls factor into categories such as 'regulation of translation' and 'chromatin modification'. The commonality in significance of ATP-dependent ion transport across group comparisons may reflect the importance of TCA cycle defects seen most noticeably in areas 45 and 47. Overall, these types of processes may categorize the unique biology of suicidal behavior in the presence or absence of depression and suggest the importance of using clinically distinguishable subtypes in future investigations into suicide.
One potential contributing factor to the gene expression findings is the terminal medical condition of the subjects from whom post-mortem tissue was obtained. While all subjects used in this study died suddenly, with no medical intervention and no prolonged agonal states, and study groups were matched for age, tissue and RNA quality, it remains a possibility that unaccounted factors play a role in the observed gene expression changes. Such factors that could be as variable as to represent lifestyle and dietary habits, or the method of death may have direct or proxy effects on our findings. However important these factors may be, it is difficult to explore their relative importance using this data set. Although they are unlikely to directly explain all findings reported here, their possible role should be investigated in future studies.
While the false discovery proportion for ventral cortical regions remains significant (ranging from 57% for BA44 to 81% for BA45), the proportion of false positives expected for DLPFC (BA46) is significantly lower (19%) in consideration of the large number of misexpressed probe sets in ANOVA. Additionally, the majority of significant genes in BA46 being misexpressed between the suicide groups (as opposed to the SMD-C comparison for the other regions analyzed) suggests both a qualitative and quantitative distinction in the role of this cortical region in suicide and depression. The investigation of a complex condition such as suicidality where the attributable risk imposed by any particular change in gene expression is likely to be minimal further emphasizes the need for careful validation of findings and cautious interpretation of data that is likely to be influenced by numerous genetic and environmental variables. With this consideration, analyses of the ventral cortical regions examined here are exploratory in nature, offering preliminary insight into the potential relevance of cortical gene misexpression in depression and suicide.
One of the first investigations of gene expression in suicide also examined orbitofrontal cortex (BA47) but did not report any significant changes related to depression following Benjamini-Hochberg correction for multiple testing. 10 While 163 genes were categorized as differentially expressed in this region for our study, we opted not to use stringent correction procedures in the initial analysis. Rather, we see microarray studies as a hypothesis-generating tool, with the strength and validity of findings resting on finding consistency and independent sample validation, criteria used in this study, as well as the accumulated body of evidence from additional studies and complementary approaches. Rather than the evidence from individual genes, a more focused picture of global changes in expression can be obtained through analysis of GO. For the dorsolateral and ventromedial regions examined in this microarray investigation, clear changes in expression of genes involved in the TCA cycle and ATPase activity, together with myelination and glial differentiation (BA46) have emerged, suggesting further avenues of research into the mechanisms conferring risk for both suicide and depression.
